References
- European Medicines Agency [Internet]. 2018 [cited 2021 May 17]. ICH E9 statistical principles for clinical trials. Available from: https://www.ema.europa.eu/en/ich-e9-statistical-principles-clinical-trials
- ICH Official web site : ICH [Internet]. [cited 2021 May 17]. Available from: https://www.ich.org/page/efficacy-guidelines
- U.S. Food and Drug Administration [Internet]. 2021 [cited 2021 May 17]. E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e9r1-statistical-principles-clinical-trials-addendum-estimands-and-sensitivity-analysis-clinical
- ICH E9(R1) EWG. ICH E9(R1) Estimands and Sensitivity Analysis in Clinical Trials. STEP 4 TECHNICAL DOCUMENT. [Internet]. [cited 2019 Dec 4]. Available from: https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf
- Lasch F, Guizzaro L, Dávila LA, Müller‐Vahl K, Koch A. Potential impact of COVID-19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA-TICS study. Pharmaceutical Statistics [Internet]. [cited 2021 Mar 10];n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/pst.2100
- Akacha M, Branson J, Bretz F, Dharan B, Gallo P, Gathmann I, et al. Challenges in assessing the impact of the COVID-19 pandemic on the integrity and interpretability of clinical trials. Statistics in Biopharmaceutical Research. 2020 Jul 1;1–18.
- Degtyarev E, Rufibach K, Shentu Y, Yung G, Casey M, Englert S, et al. Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials—Application of the Estimand Framework. Statistics in Biopharmaceutical Research. 2020 Oct 1;12(4):427–37.
- CHMP. European Medicines Agency. 2020 [cited 2021 Jun 25]. Comirnaty European Public Assessment Report. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty
- Ruberg SJ, Akacha M. Considerations for Evaluating Treatment Effects From Randomized Clinical Trials. Clinical Pharmacology & Therapeutics. 102(6):917–23.
- Akacha M. Choosing Measures of Treatment Benefit: Estimands and Beyond. CHANCE. 2019 Oct 2;32(4):12–7.
- Keene ON, Ruberg S, Schacht A, Akacha M, Lawrance R, Berglind A, et al. What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD. Pharm Stat. 2020 Jan 9;
- Permutt T. Defining treatment effects: A regulatory perspective. Clinical Trials. 2019 Feb 14;174077451983035.
- Mitroiu M, Oude Rengerink K, Teerenstra S, Pétavy F, Roes KCB. A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels? Trials. 2020 Dec;21(1):671.
- Wahab AHA, Qu Y, Michiels H, Luo J, Zhuang R, McDaniel D, et al. CITIES: Clinical trials with intercurrent events simulator. Biometrical J. 2023 Sep 22;2200103.
- Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982 Dec;38(4):963–74.
- Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. John Wiley & Sons; 2012. 742 p.
- García‐Hernandez A, Pérez T, Pardo M del C, Rizopoulos D. MMRM vs joint modeling of longitudinal responses and time to study drug discontinuation in clinical trials using a “de jure” estimand. Pharmaceutical Statistics [Internet]. [cited 2020 Aug 2];n/a(n/a). Available from: http://onlinelibrary.wiley.com/doi/abs/10.1002/pst.2045
- Burton A, Altman DG, Royston P, Holder RL. The design of simulation studies in medical statistics. Statistics in Medicine. 2006;25(24):4279–92.
- Morris TP, White IR, Crowther MJ. Using simulation studies to evaluate statistical methods. Statistics in Medicine. 2019;38(11):2074–102.
- R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. [Internet]. [cited 2020 Apr 1]. Available from: URL https://www.R-project.org/.
- Pedersen TL. patchwork: The Composer of Plots [Internet]. 2020 [cited 2021 Jun 26]. Available from: https://CRAN.R-project.org/package=patchwork
- Ripley B, Venables B, Bates DM, ca 1998) KH (partial port, ca 1998) AG (partial port, Firth D. MASS: Support Functions and Datasets for Venables and Ripley’s MASS [Internet]. 2021 [cited 2021 Jun 26]. Available from: https://CRAN.R-project.org/package=MASS
- Wickham et al., (2019). Welcome to the tidyverse. Journal of Open Source Software, 4(43), 1686, DOI: 10.21105/joss.01686.
- Pinheiro J, Bates D, DebRoy S, Sarkar D, R Core Team (2019). _nlme: Linear and Nonlinear Mixed Effects Models_. R package version 3.1-140, <URL: https://CRAN.R-project.org/package=nlme>.
- Bates D, Maechler M, Bolker [aut B, cre, Walker S, Christensen RHB, et al. lme4: Linear Mixed-Effects Models using “Eigen” and S4 [Internet]. 2021 [cited 2021 Jun 26]. Available from: https://CRAN.R-project.org/package=lme4
- The janitor package [Internet]. [cited 2021 Jun 26]. Available from: https://garthtarr.github.io/meatR/janitor.html
- Jr FEH, others with contributions from CD and many. Hmisc: Harrell Miscellaneous [Internet]. 2021 [cited 2021 Jun 26]. Available from: https://CRAN.R-project.org/package=Hmisc
- Richard Iannone, Joe Cheng and Barret Schloerke (2020). gt: Easily Create Presentation-Ready Display Tables. R package version 0.2.0.5. https://CRAN.R-project.org/package=gt.
- GitHub [Internet]. [cited 2021 Jun 25]. TheMarianMitroiuTest/Glowing-DGMs-for-outcomes-and-intercurrent-events. Available from: https://github.com/TheMarianMitroiuTest/Glowing-DGMs-for-outcomes-and-intercurrent-events
- Kenward MG, Rosenkranz GK. Joint Modeling of Outcome, Observation Time, and Missingness. Journal of Biopharmaceutical Statistics. 2011 Feb 28;21(2):252–62.
- Rizopoulos D, Lesaffre E. Introduction to the special issue on joint modelling techniques. Stat Methods Med Res. 2014 Feb 1;23(1):3–10.
- Rizopoulos D. JM: An R Package for the Joint Modelling of Longitudinal and Time-to-Event Data. ournal of Statistical Software, 35(9), 1-33 [Internet]. 2010 [cited 2021 Jun 26]. Available from: http://www.jstatsoft.org/v35/i09/
- Drugs@FDA: FDA-Approved Drugs [Internet]. [cited 2020 Apr 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020415Orig1s000rev.pdf
- Siddiqui O, Hung HMJ, O’Neill R. MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets. Journal of Biopharmaceutical Statistics. 2009 Feb 25;19(2):227–46.
- Lehmann EL, Casella G. Theory of point estimation. 2nd ed. New York: Springer; 1998. 589 p. (Springer texts in statistics).